Exagen Inc. receives conditional NY State approval for new SLE and RA biomarker assays

From GlobeNewswire: 2025-01-12 12:00:00

Exagen Inc. announces conditional approval for new SLE and RA biomarker assays, set for commercial launch in January 2025. The new biomarkers, part of the AVISE CTD platform, enhance diagnostic capabilities for autoimmune conditions. Preliminary financial results show record revenue and improved adjusted EBITDA for Q4 and full year 2024. Exagen CEO John Aballi highlights company milestones and operational progress, expressing optimism for 2025. The company cautions that final financial results may vary from preliminary numbers. Exagen specializes in autoimmune diagnostics to improve patient care and outcomes. Forward-looking statements underscore potential risks and uncertainties in Exagen’s business.



Read more at GlobeNewswire: Exagen Inc. Secures Conditional NY State Approval for New